Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free IVA Stock Alerts

Inventiva (IVA) Competitors

Inventiva logo
$3.91 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$3.98 +0.07 (+1.87%)
As of 07/2/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

IVA vs. QURE, ELVN, MOR, RARE, and TARS

Should you buy Inventiva stock or one of its competitors? MarketBeat compares Inventiva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inventiva include uniQure (QURE), Enliven Therapeutics (ELVN), MorphoSys (MOR), Ultragenyx Pharmaceutical (RARE), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "pharmaceutical products" industry.

How does Inventiva compare to uniQure?

uniQure (NASDAQ:QURE) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability and analyst recommendations.

uniQure currently has a consensus target price of $64.17, suggesting a potential upside of 53.47%. Inventiva has a consensus target price of $16.56, suggesting a potential upside of 323.42%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
1 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.65
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

uniQure has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market.

Inventiva has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Inventiva's return on equity of 0.00% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,154.42% -145.81% -27.15%
Inventiva N/A N/A N/A

In the previous week, uniQure had 22 more articles in the media than Inventiva. MarketBeat recorded 25 mentions for uniQure and 3 mentions for Inventiva. uniQure's average media sentiment score of 0.82 beat Inventiva's score of 0.23 indicating that uniQure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
uniQure
6 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.8% of uniQure shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

uniQure has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$16.10M163.79-$198.97M-$3.48N/A
Inventiva$5.07M160.19-$400.67MN/AN/A

Summary

uniQure beats Inventiva on 8 of the 15 factors compared between the two stocks.

How does Inventiva compare to Enliven Therapeutics?

Inventiva (NASDAQ:IVA) and Enliven Therapeutics (NASDAQ:ELVN) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Inventiva has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Enliven Therapeutics has lower revenue, but higher earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$5.07M160.19-$400.67MN/AN/A
Enliven TherapeuticsN/AN/A-$103.69M-$1.67N/A

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Inventiva's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
Enliven Therapeutics N/A -21.04%-20.41%

In the previous week, Enliven Therapeutics had 2 more articles in the media than Inventiva. MarketBeat recorded 5 mentions for Enliven Therapeutics and 3 mentions for Inventiva. Enliven Therapeutics' average media sentiment score of 0.93 beat Inventiva's score of 0.23 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enliven Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Inventiva currently has a consensus price target of $16.56, suggesting a potential upside of 323.42%. Enliven Therapeutics has a consensus price target of $67.83, suggesting a potential upside of 36.16%. Given Inventiva's stronger consensus rating and higher probable upside, analysts clearly believe Inventiva is more favorable than Enliven Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10
Enliven Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

Summary

Inventiva beats Enliven Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Inventiva compare to MorphoSys?

Inventiva (NASDAQ:IVA) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 323.42%. Given Inventiva's stronger consensus rating and higher possible upside, equities analysts plainly believe Inventiva is more favorable than MorphoSys.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10
MorphoSys
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

19.1% of Inventiva shares are owned by institutional investors. Comparatively, 18.4% of MorphoSys shares are owned by institutional investors. 32.0% of Inventiva shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

MorphoSys has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$5.07M160.19-$400.67MN/AN/A
MorphoSys$238.28M11.99-$205.35M-$3.48N/A

Inventiva has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Inventiva's return on equity of 0.00% beat MorphoSys' return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
MorphoSys -226.79%-694.31%-22.55%

In the previous week, Inventiva had 2 more articles in the media than MorphoSys. MarketBeat recorded 3 mentions for Inventiva and 1 mentions for MorphoSys. Inventiva's average media sentiment score of 0.23 beat MorphoSys' score of -0.71 indicating that Inventiva is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MorphoSys
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Inventiva has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market.

Summary

Inventiva beats MorphoSys on 12 of the 15 factors compared between the two stocks.

How does Inventiva compare to Ultragenyx Pharmaceutical?

Inventiva (NASDAQ:IVA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Inventiva presently has a consensus target price of $16.56, suggesting a potential upside of 323.42%. Ultragenyx Pharmaceutical has a consensus target price of $59.56, suggesting a potential upside of 77.96%. Given Inventiva's stronger consensus rating and higher possible upside, analysts plainly believe Inventiva is more favorable than Ultragenyx Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10
Ultragenyx Pharmaceutical
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.82

19.1% of Inventiva shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inventiva has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Inventiva's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
InventivaN/A N/A N/A
Ultragenyx Pharmaceutical -91.03%-1,024.42%-45.78%

In the previous week, Ultragenyx Pharmaceutical had 1 more articles in the media than Inventiva. MarketBeat recorded 4 mentions for Ultragenyx Pharmaceutical and 3 mentions for Inventiva. Ultragenyx Pharmaceutical's average media sentiment score of 1.35 beat Inventiva's score of 0.23 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ultragenyx Pharmaceutical
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Inventiva has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inventiva$5.07M160.19-$400.67MN/AN/A
Ultragenyx Pharmaceutical$673M4.90-$575M-$6.11N/A

Inventiva has a beta of 0.72, suggesting that its stock price is 28% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Summary

Inventiva beats Ultragenyx Pharmaceutical on 10 of the 15 factors compared between the two stocks.

How does Inventiva compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Inventiva (NASDAQ:IVA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

In the previous week, Tarsus Pharmaceuticals and Tarsus Pharmaceuticals both had 3 articles in the media. Inventiva's average media sentiment score of 0.23 beat Tarsus Pharmaceuticals' score of 0.14 indicating that Inventiva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tarsus Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Inventiva
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Inventiva has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Inventiva's return on equity of 0.00% beat Tarsus Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tarsus Pharmaceuticals-9.02% -14.19% -8.89%
Inventiva N/A N/A N/A

Tarsus Pharmaceuticals presently has a consensus price target of $90.67, indicating a potential upside of 38.55%. Inventiva has a consensus price target of $16.56, indicating a potential upside of 323.42%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Tarsus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tarsus Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.78
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tarsus Pharmaceuticals has a beta of 0.5, indicating that its stock price is 50% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tarsus Pharmaceuticals$451.36M6.24-$66.42M-$1.14N/A
Inventiva$5.07M160.19-$400.67MN/AN/A

Summary

Inventiva beats Tarsus Pharmaceuticals on 11 of the 14 factors compared between the two stocks.

Get Inventiva News Delivered to You Automatically

Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IVA vs. The Competition

Export
MetricInventivaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$812.13M$3.78B$7.18B$12.47B
Dividend YieldN/A2.16%2.67%6.51%
P/E RatioN/A21.6128.0224.70
Price / Sales160.19325.99534.8299.69
Price / CashN/A147.1249.2657.09
Price / Book-17.778.6610.966.46
Net Income-$400.67M$23.81M$3.57B$337.01M
7 Day Performance14.53%3.39%2.12%1.69%
1 Month Performance-2.98%10.81%5.25%3.81%
1 Year Performance27.78%62.61%33.29%23.90%

Inventiva Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IVA
Inventiva
2.741 of 5 stars		$3.91
flat		$16.56
+323.4%		+27.8%$812.13M$5.07MN/A100
QURE
uniQure
3.5677 of 5 stars		$47.24
+6.4%		$58.92
+24.7%		+188.6%$2.98B$16.10MN/A500
ELVN
Enliven Therapeutics
3.4153 of 5 stars		$48.05
+4.5%		$63.40
+31.9%		+141.0%$2.94BN/AN/A50
MOR
MorphoSys
N/A$18.96
flat		N/AN/A$2.86B$238.28MN/A730
RARE
Ultragenyx Pharmaceutical
3.8381 of 5 stars		$28.87
-0.6%		$59.56
+106.3%		-14.6%$2.85B$670MN/A1,371

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:IVA) was last updated on 7/5/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel